The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
复制标题
DOI：
10.1245/s10434-014-4274-5
复制
发表时间：
2015-07
影响因子：
3.7
通讯作者：
Herman JM
中科院分区：
文献类型：
--
作者：
Moningi S;Dholakia AS;Raman SP;Blackford A;Cameron JL;Le DT;De Jesus-Acosta AM;Hacker-Prietz A;Rosati LM;Assadi RK;Dipasquale S;Pawlik TM;Zheng L;Weiss MJ;Laheru DA;Wolfgang CL;Herman JM
立体定向全身放射治疗(SBRT)是治疗胰腺癌(PCA)的一种有前途的选择；然而，有限的数据支持其疗效。本研究回顾了SBRT治疗局部晚期(LAPC)和交界性可切除(BRPC)PCa的机构经验。我们回顾了2010-2014年间在我所接受SBRT的所有前列腺癌患者的图表。大多数患者接受SBRT前化疗。主要终点包括总生存期(OS)和局部无进展生存期(LPFS)。患者接受总剂量为25~33Gy5次。共有88名患者被纳入分析，其中74名为LAPC，14名为BRPC。LAPC和BRPC患者确诊时的中位年龄为67.2岁，中位随访期分别为14.5个月和10.3个月。确诊后中位OS为18.4个月(LAPC，18.4个月；BRPC，14.4个月)，中位PFS为9.8个月(95%可信区间8.0~12.3)。急性毒性很小，只有3名患者(3.4%)经历了≥3级急性毒性。晚期≥-2胃肠道反应5例(5.7%)。在接受手术的19名患者中(21.6%)，79%的患者是LAPC患者，84%的患者接受了切缘阴性切除。LAPC和BRPC患者在化疗后进行SBRT，急性和晚期毒性较小。尽管放射学对治疗的反应有限，但仍有很大一部分患者接受了手术切除。进一步完善化疗、SBRT和手术的整合可能会为优化患者预后提供额外的进步。
Stereotactic body radiation therapy (SBRT) is a promising option for patients with pancreatic cancer (PCA); however, limited data support its efficacy. This study reviews our institutional experience of SBRT in the treatment of locally advanced (LAPC) and borderline resectable (BRPC) PCA. Charts of all PCA patients receiving SBRT at our institution from 2010 to 2014 were reviewed. Most patients received pre-SBRT chemotherapy. Primary endpoints included overall survival (OS) and local progression-free survival (LPFS). Patients received a total dose of 25–33 Gy in five fractions. A total of 88 patients were included in the analysis, 74 with LAPC and 14 with BRPC. The median age at diagnosis was 67.2 years, and median follow-up from date of diagnosis for LAPC and BRPC patients was 14.5 and 10.3 months, respectively. Median OS from date of diagnosis was 18.4 months (LAPC, 18.4 mo; BRPC, 14.4 mo) and median PFS was 9.8 months (95 % CI 8.0–12.3). Acute toxicity was minimal with only three patients (3.4 %) experiencing acute grade ≥3 toxicity. Late grade ≥2 gastrointestinal toxicity was seen in five patients (5.7 %). Of the 19 patients (21.6 %) who underwent surgery, 79 % were LAPC patients and 84 % had margin-negative resections. Chemotherapy followed by SBRT in patients with LAPC and BRPC resulted in minimal acute and late toxicity. A large proportion of patients underwent surgical resection despite limited radiographic response to therapy. Further refinements in the integration of chemotherapy, SBRT, and surgery might offer additional advancements toward optimizing patient outcomes.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
7.7
作者：
Khashab MA;Kim KJ;Tryggestad EJ;Wild AT;Roland T;Singh VK;Lennon AM;Shin EJ;Ziegler MA;Sharaiha RZ;Canto MI;Herman JM
通讯作者：
Herman JM
DOI：
10.1016/j.ijrobp.2003.11.004
发表时间：
2004-03-15
影响因子：
7
作者：
Koong, AC;Le, QT;Bastidas, JA
通讯作者：
Bastidas, JA
DOI：
10.1186/1748-717x-8-254
发表时间：
2013-10-31
期刊：
Radiation oncology (London, England)
影响因子：
--
作者：
Rajagopalan MS;Heron DE;Wegner RE;Zeh HJ;Bahary N;Krasinskas AM;Lembersky B;Brand R;Moser AJ;Quinn AE;Burton SA
通讯作者：
Burton SA
影响因子：
2.5
作者：
Patel, Manish;Hoffe, Sarah;Malafa, Mokenge;Hodul, Pamela;Klapman, Jason;Centeno, Barbara;Kim, Jongphil;Helm, James;Valone, Tiffany;Springett, Gregory
通讯作者：
Springett, Gregory